New transplant approach aims to tame Graft-Versus-Host disease
NCT ID NCT05088356
First seen Jan 04, 2026 · Last updated Jun 16, 2026 · Updated 25 times
Summary
This early-phase study tests a stem cell transplant method for people with advanced blood cancers like leukemia. Instead of using strong drugs to prevent complications, doctors give specially selected immune cells (regulatory T-cells) along with regular T-cells to help the body accept the new stem cells while reducing the risk of graft-versus-host disease. The goal is to improve survival and quality of life after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
Stanford, California, 94304, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.